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Abstract   
Magnetic Resonance Imaging (MRI) is a well-established modality for assessing renal morphology 
and function, as well as changes that occur during disease. However, the significant metabolic 
changes associated with renal disease are more challenging to assess with MRI. Hyperpolarized 
carbon-13 MRI is an emerging technique which provides an opportunity to probe metabolic 
alterations at high sensitivity by providing an increase in the signal-to-noise ratio of 20,000-fold or 
more. This review will highlight the current status of hyperpolarised 13C-MRI and its translation into 
the clinic and how it compares to metabolic measurements provided by competing technologies such 




The kidneys account for approximately 20% of oxygen (O2) consumption in humans, second only to 
the heart (1). While renal blood flow is high, the kidneys undergo a relatively low arterio-venous 
oxygen extraction and are therefore particularly susceptible to hypoxic injury. Consequently, renal 
hypoxia plays an important role in the development and progression of both acute and chronic renal 
disease (1-3). This relationship is confounded by the heterogeneous nature of perfusion and O2 
consumption within the kidneys, as illustrated by the significant difference in pO2 between the renal 
cortex and medulla. Furthermore, of the total renal oxygen consumption of 2.7 mmol O2/(kg×min), 
about 95% of oxygen is consumed in the cortex (4). With regards to oxygen availability, it has been 
proposed that the renal medulla is divided into at least two distinct zones (5), where the deeper region 
of the medulla relies heavily on anaerobic respiration and is adapted to low pO2 levels. Although the 
outer medulla is also capable of glycolysis, this well-perfused and oxygenated region undergoes 
aerobic metabolism. Thus, in order to maintain the tubular reabsorption of water (or medullary 
concentrating ability) while avoiding tubular hypoxia, the oxygen availability and blood flow to the 
renal medulla must be closely matched to the metabolic demands of tissue. This functional 
heterogeneity is maintained through cellular diversity, in which morphologically distinct cells 
perform specialised functions enabled by distinct enzymes (6). For example, enzymes catalysing 
irreversible reactions within gluconeogenesis are located predominantly in the proximal tubular cells 
(7), while those concerned with glucose degradation are distributed mainly in more distal segments 
of the nephron (8). 
These intrarenal differences in metabolism and oxygen availability are important for the development 
of many renal diseases and imaging the spatial distribution of these changes is important for metabolic 
phenotyping and disease characterisation. Furthermore, measurements of these parameters could not 
only be used to evaluate metabolic therapies, but could also support the development of novel 
pharmaceutical agents specifically designed to improve the oxygen supply/demand balance or to 
maintain sufficient metabolism in the kidney. In this review, we outline two non-invasive diagnostic 
methods capable of imaging the renal metabolism, positron emission tomography (PET) and 
hyperpolarized magnetic resonance imaging (MRI). 
 
Positron emission tomography (PET) 
PET provides the high sensitivity and quantitative accuracy required for molecular and functional 
imaging. A number of PET imaging platforms are available, including PET in conjunction with 
computed tomography (PET/CT) or magnetic resonance imaging (PET/MRI). Both PET/CT and 
PET/MRI combine the benefits of imaging tissue anatomy, function and metabolism in one study, 
leveraging the benefits of each modality. While PET imaging has been shown to be particularly useful 
in oncology, neurology and cardiology, it is not used routinely as a clinical tool in renal diseases. The 
majority of PET tracers are radiolabelled with either 18F or 11C, but other isotopes such as 64Cu, 68Ga, 
89Zr and 124I are also used, particularly in research studies. 18F-labeled tracers offer some key technical 
and procedural advantages over 11C, including a longer half-life (109.6 vs 20.4 min), enabling 
multiple examinations in multiple patients from a single formulation and transportation to other PET 
facilities. 18F-labeled tracers also offer an intrinsically higher image resolution due to the lower 
energy and shorter range of positrons in soft tissue (9). The long half-life of 18F-labelled tracers 
restricts the possibility for retest examinations or sequential tracer examinations within the same scan 
session. Conversely, endogenous compounds can be radiolabelled with 11C without changing their 
biofunctional and metabolic properties. Moreover, 11C is a perfect radionuclide for labelling of small 
bioactive organic molecules. 
An important obstacle for PET in renal examinations is the renal handling of most clinically available 
tracers. For example, 2-18fluoro-2-deoxyglucose (18F-FDG), the most widely available PET tracer 
and a glucose analogue (Fig 1), is avidly transported and phosphorylated in metabolically active 
tissues such as many tumours, but the abundance of the 18F-FDG signal from urine makes any 
metabolic alterations present in disease states very difficult to assess in the kidney. The accumulation 
of 18F-FDG in the urine is due to the reduced affinity of the sodium glucose cotransporter for tubular 
reabsorption of 18F-FDG compared to glucose; unlabelled glucose is largely retained in the body by 
active reabsorption (10) and therefore undergoes very different renal handling. While this has limited 
the application of 18F-FDG-PET in studies of kidney metabolism, Hato et al. have demonstrated an 
increased cortical 18F-FDG uptake following the pharmacological inhibition of the gene p53 (p53 
regulates genes in pathways such as oxidative respiration and glycolysis for energy generation and 
glucose homeostasis) (9), providing a proof of concept that PET can detect changes in cellular glucose 
utilisation. 
11C-labelled compounds have also been investigated for investigating the renal metabolism. Shreve 
et al. have recently demonstrated excellent renal imaging obtained by PET using 11C-acetate (11), 
and this approach was suggested as a biomarker for renal oxidative metabolism via the tricarboxylic 
acid cycle (12). Recently, Splan et al. showed that 11C-choline successfully reveals the renal tubular 
function (13). H2
15O has been used as a non-invasive clinical tracer to image tissue blood flow (Fig 
2). H2
15O, is a particularly suitable renal perfusion biomarker because it is diffusible and is neither 
extracted nor metabolised in the kidney and has a short half-life (2 min), allowing multiple 
examinations during the same scan session (14) (Fig 1). 
 
Hyperpolarised 13C-MRI  
Hyperpolarised 13C-MRI is an emerging molecular imaging method that allows rapid, non-invasive 
and pathway-specific investigation of dynamic, metabolic and physiologic processes, previously not 
possible with imaging. Hyperpolarised 13C-labelled agents enhance the signal-to-noise ratio in vivo 
more than 20,000-fold compared to conventional, non-hyperpolarised 13C-MRI and is capable of 
capturing perfusion, uptake and subsequent metabolic conversion of tracers and could have great 
potential in studying metabolic renal disorders (15-18) (Fig 3). 
Hyperpolarised 13C-based bioprobes enable direct quantification of tracer concentrations similar to 
tracers in PET scans, where the tracer itself emits the signal rather than modulating the surrounding 
tissue, as seen in standard contrast-enhanced MRI. Hyperpolarised MRI utilises molecules labelled 
with 13C (or other MR-active nuclei), which undergo dynamic nuclear polarisation (DNP) and rapid 
dissolution to create an injectable solution (19-21). Following injection of a hyperpolarised substrate, 
the enzymatic conversion of the injected substrate can be detected. DNP relies on the principle of 
transferring a higher polarisation or energy level from one spin (typically electrons) to another nuclear 
spin (typically 13C) (20, 21). This process is accomplished by irradiating electrons with a microwave 
frequency that matches the resonance frequency of the combined system of electron and 13C-nuclear 
spins. In order to achieve maximum polarisation of the target nuclear spin, the spins system is cooled 
to <1 K (-272 C). The process to polarise 13C-containing molecules takes approximately 2 h, 
typically using a magnetic field strength of 5 T. After the sample has polarised, it is rapidly heated 
and administered by venous bolus injection to the subject within the MRI system, similar to 
conventional contrast-agent administration (21). 
Pioneering work by Golman et al. showed the potential of hyperpolarised MRI in renal diagnostics 
(22), demonstrating catheter tracking, renal angiography and perfusion assessment (23). Furthermore, 
the technique holds the potential for in situ tracing of metabolic conversion of injected metabolic 
bioprobes to their product metabolites in renal tissue (24, 25). Following these discoveries, several 
hyperpolarised substances have been proposed as new potential diagnostic markers in renal disease. 
The most well-established substance is hyperpolarised [1-13C]pyruvate, the first hyperpolarised 
bioprobe to be assessed in humans (16, 18). 
 
Imaging glycolysis with [1-13C]pyruvate  
Following intravenous injection of hyperpolarised [1-13C]pyruvate, the molecule is distributed in the 
blood and transported intracellularly, particularly in well-vascularised and perfused organs such as 
the kidneys (17, 18). Pyruvate, the end-product of glycolysis, undergoes oxidation in the 
mitochondria by entering the tricarboxylic acid (TCA) cycle via pyruvate dehydrogenase, 
transamination in the cytosol via alanine transaminase (ALT) forming alanine or, under anaerobic 
conditions, conversion to lactate via lactate dehydrogenase (LDH) (Fig 4). The injected pyruvate and 
its metabolism can be detected by the chemical shift of the product and substrates on MR 
spectroscopy i.e. the conversion of [1-13C]pyruvate (detected at 170.4 ppm) to [1-13C]lactate (183 
ppm), [1-13C]alanine (176 ppm) and 13CO2 (125 ppm)/H
13CO-3 (160 ppm). The ability to investigate 
multiple metabolic pathways (aerobic and anaerobic) in one single examination within a couple of 
minutes offers a new approach to imaging haemodynamics and metabolism simultaneously using 
MRI (23, 26-37). By labelling the molecular C2 position instead of the C1 position of pyruvate 
molecules, the 13C label can be detected within the TCA cycle (38). 
In a rat model of streptozotocin-induced type-1 diabetes, hyperpolarised [1-13C]pyruvate and BOLD 
1H-MRI were employed to investigate changes in renal physiology in vivo (39). In that study, diabetic 
kidneys showed an increased metabolic flux in anaerobic pathways, such as an increased 
lactate/pyruvate ratio compared to healthy kidneys, whereas the bicarbonate/pyruvate ratio, a 
surrogate marker for aerobic metabolism, remained unchanged. This oxygen metabolic 
reprogramming was paralleled by a reduced intrarenal oxygen availability and/or increased 
consumption identified by oxygen-dependent hyperpolarised 13C-urea T2-weighted imaging (40) and 
by BOLD MRI (39). In another study, streptozotocin-induced diabetic rats were exposed to 
alternating oxygen concentration in the inspired air, which altered renal tissue oxygenation (41). The 
renal metabolic effects were studied using hyperpolarised [1-13C]pyruvate MRI and BOLD 1H-MRI, 
demonstrating that the reduced oxygen availability in the diabetic kidney altered energy metabolism 
via increased lactate and alanine formation, while the bicarbonate flux remained unchanged. Thus, 
these results support the view that the increased prevalence and severity of nephropathy in patients 
with diabetes at high altitudes may originate from increased oxygen sensitivity (41), and that 
hyperpolarised MRI shows promise in the diagnosis and monitoring of early renal changes associated 
with diabetes. Importantly, lactate production not only correlates with the severity of renal 
dysfunction and its progression, it also represents a novel measure of therapeutic response. Similar to 
hypoxia, glucose-lowering drugs such as insulin and metformin treatment in diabetic rats have been 
shown to increase lactate production while LDH inhibitor therapies, such as hyperbaric oxygen 
therapy and antioxidant treatment, have shown to reduce renal lactate production (27, 31, 37, 42-44). 
The kidney not only consumes glucose, but it may also generate glucose as part of gluconeogenesis. 
In the renal cortex, gluconeogenic enzymes (phosphoenolpyruvate carboxykinase (PEPCK), fructose-
1,6-bisphosphatase glucose-6-phosphatase) synthesise glucose-6-phosphate from precursors such as 
lactate, glutamine, glycerol and alanine (37, 44). Alterations in the renal redox balance imposed by 
inhibition of the gluconeogenic pathway via 5' adenosine monophosphate-activated protein kinase 
have been investigated using hyperpolarised [1-13C]pyruvate (31, 45). However, more specific 
biomarkers such as [1-13C]dehydroascorbate (DHA), [2-13C]dihydroxyacetone, 13C-glycerate or [1-
13C]alanine could provide additional insight, particularly in pre-clinical research (46-49). 
Many mutations commonly observed in renal cell carcinoma (RCC) result in changes in the cellular 
energy metabolism (50). Additionally, metabolic alterations and increased concentrations of 
oncometabolites, such as succinate and fumarate, have increasingly recognised roles in tumorigenesis 
(51). Hyperpolarised [1-13C]pyruvate MRI can be used to investigate altered tumour energy 
metabolism, where an increased pyruvate-to-lactate ratio is associated with malignancy and tumour 
aggressiveness in in vitro models of RCC (52, 53). In perspective, this MRI technique could play a 
role in early detection of treatment response in patients undergoing systemic anticancer therapy to 
ensure treatment efficacy and limit side-effects. For example, metabolic response to mTOR 
(mechanistic target of rapamycin) inhibition, a therapeutic target in RCC, can be observed as early as 
24 hours after the initiation of treatment in a murine model (52). Initial patient data confirm that 
hyperpolarised imaging is feasible in patients with RCC and highlight the need for further clinical 
research to define the future role of this modality in uro-oncological imaging (54).  
Hyperpolarised [1-13C]pyruvate has also shown promising results in unilateral ureteral obstruction 
(26), acute kidney injury (both ischaemia/reperfusion and toxin-induced), as well as acute tubular 
necrosis (36, 55, 56). Taken together, these findings support a potential clinical use of hyperpolarised 
[1-13C]pyruvate, although only few reports have investigated renal dysfunction in humans or animal 
models of renal disease (24, 29, 54). 
 
Emerging clinical biomarkers 
Clatworthy et al. have shown that [1-13C]pyruvate metabolism was unaltered in a model of acute 
tubular necrosis while [1,4-13C2]fumarate revealed early tubular necrosis through an enzymatic 
conversion of fumarate to malate catalysed by the enzyme fumarase. As fumarate is transported 
slowly into viable cells, its physiological conversion to malate is minimal and the detection of malate 
signal on MRI is associated with cell death in early tubular necrosis (56) and ischaemia/reperfusion 
injury (57). Another emerging hyperpolarised compound in renal MRI diagnostics is acetate, which 
is rapidly metabolised into acetylcarnitine in mammalian cells. Koellisch et al. demonstrated that 
conversion of 13C-acetate to 13C-acetylcarnitine is detectable in the kidney with an advanced MRI 
acquisition strategy, although they showed no differences between diabetic and healthy kidneys (58). 
By repurposing a kinetic analysis approach developed for 11C-acetate PET, it is possible to map the 
metabolic clearance rate of 13C-acetate, similar to that reported in 11C-acetate PET studies (59). 
Keshari et al. have shown increased oxidative stress in diabetic mouse kidneys using the novel redox 
sensor, hyperpolarised [1-13C]DHA (48). Interestingly, that study highlighted the potential of 
investigating oxidative stress modulation, and the authors suggested that hyperpolarised [1-13C]DHA 
may potentially enhance the prediction and early detection of diabetic nephropathy and provide 
companion biomarkers that can better inform about the response to new therapies targeting oxidative 
stress in patients. An alternative approach for assessing the intrarenal redox state has recently been 
demonstrated by Von Morze et al. (60) using 13C-acetoacetate. 13C-acetoacetate to 13C--
hydroxybutyrate conversion is directly linked to the mitochondrial redox state. 
The intrarenal osmolality-gradient is driven by the active transport of ions and water and is closely 
linked to renal function. A particularly appealing emerging clinical probe for renal investigations is 
the osmolite 13C-urea, which has been demonstrated in pre-clinical models to allow assessment of 
pathological changes in kidney diseases (28, 32, 61), as well as functional states such as the difference 
between hydration and diuresis (35, 62, 63). By utilising [13C,15N]urea as a probe, it is possible to 
increase the longitudinal and transverse relaxation times (T1 and T2 relaxation) of the hyperpolarised 
state, and thus, [13C,15N]urea could potentially be used in future clinical studies, thereby extending 
the imaging window (33). As urea shows many biochemical characteristics similar to water, urea 
relaxation properties might be used to differentiate physiological and diseased states similar to 
conventional functional proton MRI methods such as BOLD (64, 65). Furthermore, rodent data 
suggests that besides perfusion, the [13C,15N]urea first-pass uptake-curve may reflect renal GFR (66), 
and could be used instead of gadolinium-containing contrast-agents (67-69) extending what is 
possible with non-contrast enhanced methods such as arterial spin labelling. Hyperpolarised H2O 
could provide haemodynamic information inside the kidneys in a way similar to H2
15O PET, with the 
advantage of providing angiographic imaging owing to the increased temporal resolution of MRI 
compared to PET (70). 
 
Discussion 
The metabolic status of the kidney may indicate susceptibility to injury and is considered a measure 
of progression in many renal disease processes. However, non-invasive clinical methods to image 
kidney metabolism are lacking. In this review, we have addressed methods for imaging oxygenation 
and metabolism in the kidney. The complex pathophysiology of renal disease is tightly connected 
with metabolic alterations. Despite developments in the mechanistic understanding of renal diseases, 
the potential causality between metabolic changes and disease development is poorly understood. 
Overt diabetic nephropathy, for example, is characterised by proteinuria, a decline in renal function, 
decreasing GFR, glomerulosclerosis and interstitial fibrosis (71); however, accurate and non-invasive 
biomarkers of disease progression are needed to monitor the multifactorial progression associated 
with the metabolic, functional and haemodynamic status in this and other renal diseases (72). 
Hyperpolarised MRI is promising but still lacks largescale and widespread validation and 
implementation in clinical kidney examinations. Like the sterile environment in every PET facility, 
production and use of hyperpolarised nuclei are subject to production criteria, ensuring a safe and 
injectable product. The tolerability of the intravenous injected supraphysiological concentration of 
(0.43ml/kg 250 mM) pyruvate has been shown to be high in humans (18, 54, 73-77). [1-13C]pyruvate 
is the first hyperpolarised bioprobe available for human use, but other candidate clinical molecules 
are being developed, including [2-13C]pyruvate, [1,4-13C]fumarate, 13C-urea and [1-13C]lactate. 
In conclusion, MRI is a powerful non-invasive tool for renal imaging, where functional and 
morphological information can aid both researchers and clinicians. An important advantage of MRI 
is the lack of ionising radiation, allowing repeated measurements over the course of a disease. 
Hyperpolarised MRI increases the sensitivity of MRI by several orders of magnitude and has shown 




Table 1: Metabolic and functional imaging biomarkers for renal imaging. 
 
Compound Modality Pathway/function Strength Weakness References 
2-18F-2-Deoxyglucose 
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H2150 PET Perfusion Short half-life Short half-life (79) 
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position.   
Low intracellular 
pyruvate pool.  
(37) 
13C-urea or [13C,15N2]urea HP Perfusion, function High polarisation 
and long lived 
(15N) 
14N is a 
quadrupolar spin.  
(35, 62) 
[1,4-13C]fumarate HP Cell death Almost binary 
cell death marker 
Splitting of the 
peaks.  
(35) (57) 
13C-Acetate HP Perfusion, 
tricarboxylic acid 
cycle flux 





HP Perfusion Very long lived Relative low SNR 
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(81, 82) 








1H2O HP Angiogram/Perfusion High SNR; no 





















Fig 1. Metabolism of tracers used in renal imaging. Pyruvate is taken up into the cell through the 
monocarboxylate transporter 1 (MCT1) and rapidly metabolised in the cytosol to lactate and alanine. 
Following mitochondrial uptake through the mitochondrial pyruvate carrier (MPC), pyruvate 
dehydrogenase (PDH) catalysis the formation of Acetyl-CoA and transfer of the 13C-label to 
bicarbonate. Downstream metabolites of [1-13C]pyruvate can be spectrally resolved, which stands in 
contrast with FDG. After uptake through the GLUT1 transporter, FDG undergoes hexokinase (HK) 
mediated phosphorylation and FDG-6P is fixated in the cell. MR-active [2-13C]acetate and 
radioactive [1-11C]acetate are rapidly metabolised to Acetyl-CoA and taken up into the mitochondria 
where they enter the citric acid cycle or fatty acid synthesis. Fumarate hydratase (FH) is released 
from cells undergoing necrosis as a result of increased membrane permeability, resulting in rapid 
conversion of fumarate to malate. 
ACS: Acetyl-CoA synthetase, Ala: Alanine, ALT: Alanine Aminotransferase, ATL: Acetylcarnitine 
Translocase, Bic: Bicarbonate, CAT: Carnitine O-Acetyltransferase, CoA: Coenzyme A, FDG: 
Fluorodeoxyglucose, FDG-6P: Flurodeoxyglucose 6-phosphate, FH: Fumarate Hydratase, GLUT: 
Glucose Transporter, HK: Hexokinase, Lac: Lactate, LDH: Lactate Dehydrogenase, MCT: 
Monocarboxylate Transporter, MPC: Mitochondrial Pyruvate Carrier, Pyr: Pyruvate. 
 
 
Fig 2. Renal blood perfusion measurement by PET using H2
15O. The dynamic uptake of the 




Fig 3. A hyperpolariser can make use of the dynamic nuclear polarisation (DNP) methodology, which 
is able to transfer excess heat or energy from the electron spin to the nuclear spin of choice (for 
example 13C). This energy transfer is achieved by freezing the sample (-272 ºC), in a strong magnet 
field (usually 3-5 T), and by irradiating the sample with microwaves with a specific frequency 
determined by the magnetic field and the nuclear spins of interested. The sample are finally 




Fig 4: (Top left) single time point [1-13C]pyruvate image showing the pyruvate distribution 20 s after 
injection. (Top right) a cortical ROI signal change for 60 s. (Lower left-right) [1-13C]lactate and [1-
13C]alanine distribution normalised to the generated metabolites (from the injected [1-13C]pyruvate), 
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